The experimental vaccine, VSV-EBOV, has been the subject of a study in Geneva since November 2014
Mathilde Missioneiro / WHO
The University of Geneva is to lead an EU research project using data from the Ebola vaccine trials underway at Geneva University Hospital (HUG). The aim is to understand in detail the vaccine’s effect on the immune system.
This content was published on
1 minute
swissinfo.ch and agencies
Twelve partner institutions from across Europe, Africa and the US will take part, the hospital said on Friday.
The work will run for three years and will cost almost €4 million (CHF ).
A total of 115 volunteers are involved in testing out the potential vaccine, samples from these ongoing trials at the hospital will be used for the data.
The researchers will compare almost 20,000 genes to find out why the volunteers reacted differently to the VSV-ZEBOV vaccine.
“We have in our possession a unique number of samples that make up an exceptional database,” Claire-Anne Siegrist, head of the Center of Vaccinology of the Geneva University Hospital, said in a press release.
The vaccine study in Geneva was temporarily suspended in December 2014 after some of the participants complained of unexpected but mild joint pain in their hands and feet. The trial resumed in January using a lower dose of the drug.
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Ebola vaccine trials to resume in Geneva
This content was published on
The tests had been suspended on December 11 as a precautionary measure after some volunteers reported unexpected side effects. The trial was scheduled to resume in January. The study researchers had reported four cases of mild joint pain in the hands and feet of people who had received the shot ten to 15 days earlier.…
This content was published on
In a statement issued on Thursday, Geneva University Hospital said the trial had been suspended. The study, so far involving 59 people, began in November. Researchers reported four cases of mild joint pain in the hands and feet of people who received the shot ten to 15 days earlier. Officials will stop giving the vaccine…
Cuban doctor leaves Geneva after recovering from Ebola
This content was published on
The 43-year-old man was one of 256 Cuban doctors and nurses who went to West Africa to treat patients from the worst outbreak of the virus on record, which has killed more than 6,000 people. He had arrived in Geneva on November 20 – having contracted the disease in Sierra Leone – and was taken by ambulance to…
This content was published on
Geneva University Hospital (HUG) received approval from Swissmedic on Thursday to begin trials of a new type of Ebola vaccine received in October from the Canadian National Microbiology Laboratory. The trials will commence on November 10. After approval from the ethics committees of the Canton of Geneva and the World Health Organisation (WHO), HUG was…
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.